Search
Close this search box.

Sensus Healthcare Appoints Dr. Ziv Karni as Chief Scientific Officer

Medical Laser Pioneer and Veteran Entrepreneur Brings Over 30 Years of Experience to Company BOCA RATON, Fla., Feb. 28, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the Company has appointed Dr. Ziv Karni to the role […]

All about Keloid Scar Removal

Keloid scar removal is often an elusive task. This leaves many people living with unsightly scarring when the fact is they don’t need to! Here’s what you need to know about treating keloids most effectively. What Are Keloids? If you haven’t suffered from them, chances are that you have never heard of keloids. However, keloids […]

U.S. FDA Grants Market Clearance to Sensus Healthcare’s New Sculptura™ Radiation Oncology System

A Single Treatment during Surgery, Sculptura™ Eliminates Weeks of Post-Operative Radiation for Cancer Patients BOCA RATON, Fla., Feb. 26, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that the U.S. Food and Drug Administration (FDA) has granted market […]

Sensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth

Shipped 27 systems during the quarter including 15 SRT-100 Vision™ systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 14, 2019 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces financial results […]

Leading Dermatologists Develop Consensus Guidelines for the Use of Superficial Radio Therapy to Treat Non-Melanoma Skin Cancers and Keloids

Published in The Journal of Clinical and Aesthetic Dermatology, Consensus was Reached that SRT is Safe, and Effective in Treating SCC and BCC and Should be Considered as the First-Line Form of Radiation Treatment. BOCA RATON, Fla., Feb. 14, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment […]

Cure Rate Exceeds 97 Percent in Retrospective Study of Sensus Healthcare’s SRT-100™ for Treating Basal and Squamous Cell Carcinomas of the Lower Extremities

Data from this Non-Invasive, Highly Effective Treatment Option for Non-Melanoma Skin Cancer Published in Journal of Drugs in Dermatology BOCA RATON, Fla., Feb. 12, 2019 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radio Therapy (IGSRT), announces the […]